OncoMatch/Clinical Trials/NCT07039916
Study to Assess the Efficacy and Safety of IMVT-1402 in Participants With Mild to Severe Generalized Myasthenia Gravis
Is NCT07039916 recruiting? Yes, currently enrolling (Jun 2026). This Phase 3 trial studies multiple treatments including IMVT-1402 and IMVT-1402 for generalized myasthenia gravis.
Treatment: IMVT-1402 · IMVT-1402 · IMVT-1402 — The purpose of the study is to assess the efficacy, safety and tolerability of IMVT-1402 in adult participants with mild to severe generalized myasthenia gravis.
Check if I qualifyExtracted eligibility criteria
Treatments studied
Other
Disease stage
Required: Stage CLASS II, CLASS III, CLASS IVA (Myasthenia Gravis Foundation of America (MGFA))
MGFA classification of Class II, III, or IVa at the Screening Visit
Demographics
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- Site Number - 1041 · Mobile, Alabama
- Site Number - 1017 · Phoenix, Arizona
- Site Number - 1025 · Scottsdale, Arizona
- Site Number - 1042 · Tucson, Arizona
- Site Number - 1010 · Carlsbad, California
Showing up to 5 US sites.
See all sites on ClinicalTrials.gov →Frequently asked questions
Is NCT07039916 currently recruiting?
Yes, this trial is currently recruiting patients.
What disease stage is eligible?
Stage CLASS II or CLASS III or CLASS IVA is required.
Is there an age limit?
Yes. Patients must be 80 years or younger.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify